vipor: a multi-targeted therapy for the treatment of r/r dlbcl
Published 6 months ago • 137 plays • Length 2:15Download video MP4
Download video MP3
Similar videos
-
2:30
vipor regimen for r/r b-cell lymphoma
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl
-
0:42
targeted therapies for dlbcl treatment
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
1:52
an insight into the optimal management of patients with dlbcl
-
7:16
changes in the classification of dlbcl
-
1:02
maintenance therapy following treatment for amyloidosis
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
7:48
glofitamab, a cd20/cd3 bispecific antibody, in the treatment of r/r dlbcl
-
2:40
btk inhibitors for r/r mcl: current uses and insights from the vipor study
-
0:45
difference between quality of life & patient-reported outcomes
-
0:58
improving second-line treatments in dlbcl
-
3:05
car-t therapy in r/r dlbcl
-
5:04
efficacy and safety of m-pola for r/r b-cell nhl
-
3:58
extended follow-up of glofitamab monotherapy in r/r lbcl: durability of cr and likelihood of crs
-
1:51
efficacy of odronextamab in r/r dlbcl & determining the optimal sequencing of immune therapies
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl